文献速递骨质疏松与代谢性骨病

特立帕肽致持续性高钙血症:一例病例报告及文献综述

Prolonged hypercalcemia induced by teriparatide: a case report and literature review.
PubMed 文献 · Osteoporos Int · 2025-06-11

一例76岁女性绝经后合并糖皮质激素性骨质疏松患者,在依替膦酸、阿仑膦酸和地舒单抗治疗失败后于2023年5月5日启用特立帕肽,3个月后出现持续性无症状高钙血症,血钙峰值11.78 mg/dl(2023年9月27日),停药后于2023年10月31日血钙恢复正常。作者认为相对「过量」的累积效应可能是原因,鉴于患者BMI为14.42 kg/m2但接受标准剂量20 mcg每日皮下注射,提示对高钙血症风险患者需保持监测警惕,并呼吁进一步研究个体化给药策略。

要点

  • 特立帕肽治疗3个月后出现持续性无症状高钙血症,血钙峰值11.78 mg/dl。
  • 停药后血钙于2023年10月31日恢复正常。
  • 患者BMI 14.42 kg/m2但接受标准剂量20 mcg每日皮下注射。

核心结论

  • 特立帕肽相对「过量」的累积效应可能是该例持续性高钙血症的促发因素。
  • 该病例强调在使用特立帕肽期间对高钙血症风险患者需保持监测警惕。
  • 该病例提示需进一步研究个体化给药策略,例如在体重不足患者中。

研究设计与样本

  • 病例报告及文献综述。
  • 患者为76岁女性,有绝经后骨质疏松和糖皮质激素诱导的骨质疏松,背景为自2005年起的类风湿关节炎。

主要发现

  • 启用特立帕肽前连续血清钙水平均正常。
  • 特立帕肽治疗3个月后出现持续性无症状高钙血症,2023年9月27日血钙峰值11.78 mg/dl。
  • 自2023年9月27日停用特立帕肽,2023年10月31日血钙恢复正常。
  • 患者BMI为14.42 kg/m2,但接受标准剂量20 mcg特立帕肽每日皮下注射。

临床怎么用

  • 作者认为特立帕肽相对「过量」的累积效应可能是该例持续性高钙血症的促发因素。
  • 作者指出该病例强调在使用特立帕肽期间对高钙血症风险患者需保持监测警惕。
  • 作者提出该病例提示需进一步研究个体化给药策略,例如在体重不足患者中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teriparatide is indicated for the treatment of osteoporosis with a high risk of fractures. While transient hypercalcemia is a commonly reported side effect, we report a case of prolonged hypercalcemia associated with teriparatide. The patient was a 76-year-old female who had postmenopausal and glucocorticoid-induced osteoporosis on the background of rheumatoid arthritis since 2005. After failing treatment with etidronate, alendronate, and denosumab in view of minimal improvement in bone density and multiple fragility fractures, she was started on teriparatide on 5 May 2023. Serial serum calcium levels were all normal before the initiation of teriparatide. However, she was noted to have prolonged asymptomatic hypercalcemia after 3 months of teriparatide therapy, with a peak calcium level of 11.78 mg/dl on 27 September 2023. Teriparatide was discontinued since 27 September 2023 and normalization of serum calcium was noted on 31 October 2023.The cumulative effect of teriparatide from relative "overdosing" may be a contributing factor for prolonged hypercalcemia in our case, given she had a body mass index of 14.42 kg/m2 but received the standard dose of 20 mcg teriparatide subcutaneously daily. This case underscores the necessity for vigilance in monitoring patients at risk of hypercalcemia during teriparatide therapy. Furthermore, it prompts further investigation into personalized dosing strategies, i.e., in underweight patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Lin J, Tjokrosaputro PP, Ang BH, et al. Prolonged hypercalcemia induced by teriparatide: a case report and literature review. Osteoporos Int. 2025. PMID: 40500389. doi:10.1007/s00198-025-07569-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。